Cost of New PCSK9 Inhibitors May Overwhelm Patients and Payers

A new class of injectable cholesterol-lowering drugs, PCSK9 inhibitors, are good news for patients who are unresponsive to statins, but their current price. How will payers make this work? Read more here. (Source: Tracey Walker, Managed Healthcare Executive, 9/2/15)

You might also be interested in:

Are Payers Warming Up to Pricey Cholesterol Drugs? April 16, 2018
Amgen to Cut Price of Cholesterol Drug by 60% October 26, 2018
Regeneron, Sanofi to Cut Price of Praluent March 12, 2018
ICER Releases Final New Evidence Update for Alirocumab February 15, 2019
Analysis: Amgen’s Repatha Money-Back Guarantee May Fall Short April 10, 2018
Article: Price Drops on Praluent, Repatha Boon for Patients February 12, 2019
Column: Sanofi, Regeneron’s Praluent Gamble Worth It March 21, 2018